These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 26845923)

  • 1. [Mechanism of regulation of HCV replication by miR-122].
    Shimakami T; Kaneko S
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():160-4. PubMed ID: 26845923
    [No Abstract]   [Full Text] [Related]  

  • 2. Depletion of MicroRNA-373 Represses the Replication of Hepatitis C Virus via Activation of Type 1 Interferon Response by Targeting IRF5.
    Gong W; Guo X; Zhang Y
    Yonsei Med J; 2018 Dec; 59(10):1181-1189. PubMed ID: 30450852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA profile before and after antiviral therapy in liver transplant recipients for hepatitis C virus cirrhosis.
    Gelley F; Zadori G; Nemes B; Fassan M; Lendvai G; Sarvary E; Doros A; Gerlei Z; Nagy P; Schaff Z; Kiss A
    J Gastroenterol Hepatol; 2014 Jan; 29(1):121-7. PubMed ID: 24033414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of microRNA-199a-5p reduces the replication of HCV via regulating the pro-survival pathway.
    Wang H; Gao H; Duan S; Song X
    Virus Res; 2015 Oct; 208():7-12. PubMed ID: 26027911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in microRNA expression profile in HCV-infected hepatoma cells: involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway.
    Ishida H; Tatsumi T; Hosui A; Nawa T; Kodama T; Shimizu S; Hikita H; Hiramatsu N; Kanto T; Hayashi N; Takehara T
    Biochem Biophys Res Commun; 2011 Aug; 412(1):92-7. PubMed ID: 21802413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus replication in mouse cells is restricted by IFN-dependent and -independent mechanisms.
    Nandakumar R; Finsterbusch K; Lipps C; Neumann B; Grashoff M; Nair S; Hochnadel I; Lienenklaus S; Wappler I; Steinmann E; Hauser H; Pietschmann T; Kröger A
    Gastroenterology; 2013 Dec; 145(6):1414-23.e1. PubMed ID: 23973921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus and human miR-122: insights from the bench to the clinic.
    Wilson JA; Sagan SM
    Curr Opin Virol; 2014 Aug; 7():11-8. PubMed ID: 24721497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular biology of hepatitis C infection.
    Drazan KE
    Liver Transpl; 2000 Jul; 6(4):396-406. PubMed ID: 10915159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets.
    Suzuki T
    Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A primer on the molecular virology of hepatitis C.
    Moradpour D; Blum HE
    Liver Int; 2004 Dec; 24(6):519-25. PubMed ID: 15566499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary daidzein inhibits hepatitis C virus replication by decreasing microRNA-122 levels.
    He Y; Huang M; Tang C; Yue Y; Liu X; Zheng Z; Dong H; Liu D
    Virus Res; 2021 Jun; 298():198404. PubMed ID: 33775754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Existing and future therapeutic options for hepatitis C virus infection.
    Bretner M
    Acta Biochim Pol; 2005; 52(1):57-70. PubMed ID: 15827606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting miRNAs to treat Hepatitis C Virus infections and liver pathology: Inhibiting the virus and altering the host.
    Thibault PA; Wilson JA
    Pharmacol Res; 2013 Sep; 75():48-59. PubMed ID: 23541631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice.
    McHutchison JG; Bartenschlager R; Patel K; Pawlotsky JM
    J Hepatol; 2006 Feb; 44(2):411-21. PubMed ID: 16364491
    [No Abstract]   [Full Text] [Related]  

  • 15. The way forward in HCV treatment--finding the right path.
    Manns MP; Foster GR; Rockstroh JK; Zeuzem S; Zoulim F; Houghton M
    Nat Rev Drug Discov; 2007 Dec; 6(12):991-1000. PubMed ID: 18049473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HCV/HIV co-infection therapy.
    Pietrandoni G
    Posit Aware; 2002; 13(2):32, 38. PubMed ID: 12004829
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation systems for anti-HCV drugs.
    Moriishi K; Matsuura Y
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to direct antiviral agents in patients with hepatitis C virus infection.
    Sarrazin C; Zeuzem S
    Gastroenterology; 2010 Feb; 138(2):447-62. PubMed ID: 20006612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of small molecule modifiers of microRNAs for the treatment of HCV infection.
    Tripp VT; Young DD
    Methods Mol Biol; 2014; 1103():153-63. PubMed ID: 24318893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D cultured immortalized human hepatocytes useful to develop drugs for blood-borne HCV.
    Aly HH; Shimotohno K; Hijikata M
    Biochem Biophys Res Commun; 2009 Feb; 379(2):330-4. PubMed ID: 19103167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.